Maximizing survival and minimizing toxicity

Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer

(2010) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of p16INK4Aand Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

(2010) Danny Rischin et al.   JOURNAL OF CLINICAL ONCOLOGY

Intensity-Modulated Chemoradiotherapy Aiming to Reduce Dysphagia in Patients With Oropharyngeal Cancer: Clinical and Functional Results

(2010) Felix Y. Feng et al.   JOURNAL OF CLINICAL ONCOLOGY

Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02

(2010) Lester J. Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

(2010) K. Kian Ang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels

(2008) J. K. Salama et al.   ANNALS OF ONCOLOGY